The most common NSCLC fusions that are considered responsible for acquired resistance to third-generation TKIs include SPTBN1-ALK, RET–ERC1 and FGFR3–TACC3, with CCDC6–RET, NCOA4–RET, NTRK1–TPM3, AGK–BRAF, GOPC-ROS1 and ESYT2–BRAF. Here, ERC1 is linked to non-small cell lung carcinoma.